CRNX vs LIVN
Crinetics Pharmaceuticals, Inc. vs LivaNova — AI-powered side-by-side comparison
CRNX
Crinetics Pharmaceuticals, Inc.
69
Buy
VS
| Metric | CRNX | LIVN |
|---|
| AI Score |
69
|
70
|
| Price |
$84.69
|
$82.25
|
| P/E Ratio |
-16.77×
|
23.83×
|
| ROE |
-46.9%
|
-20.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.2%
|
68.2%
|
| Debt / Equity |
0.04×
|
0.27×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
60.6
|
| Beta |
0.1302
|
0.872
|
| Expected Upside |
—
|
+0.8%
|
AI Committee View
Current Innellis committee reasoning for CRNX versus LIVN.
LIVN leads by 1 points.
LIVN scores 70/100 (Buy) versus CRNX at 69/100 (Buy).
CRNX Committee View
80% agreement
5 analysts
The primary driver is 3 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 90 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 90 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
LIVN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- ROE of 15.4% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Risk/reward is unfavorable: 5.6% downside vs 0.8% upside.